Clinical significance of VEGF levels in serums of colorectal cancer patients at stage IV.
- Author:
Na HUANG
1
;
Lin YANG
;
Meng-ran CAO
;
Ning SU
;
Jin-zhang CHEN
;
Cheng-wei LÜ
;
Wang-jun LIAO
;
Rong-cheng LUO
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Antibodies, Monoclonal; administration & dosage; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Bevacizumab; Colorectal Neoplasms; blood; drug therapy; pathology; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Middle Aged; Neoplasm Staging; Vascular Endothelial Growth Factor A; blood; Young Adult
- From: Journal of Southern Medical University 2009;29(2):278-279
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the clinical significance of vascular endothelial growth factor (VEGF) levels in serums of colorectal cancer patients at stage IV.
METHODSUsing enzyme linked immunosorbent assay (ELISA) to detect the VEGF levels in serums of 45 colorectal cancer patients at stage IV, and 20 healthy served as normal control.
RESULTSThe mean concentration of VEGF in 45 colorectal cancer patients at the 7 day after operation were significantly lower than that before operation (P<0.01). The mean concentration of VEGF in the patients who benefit from bevacizumab showed no statistical difference from the levels of who did not benefit (P=0.554).
CONCLUSIONThe VEGF levels in colorectal patients at stage IV are lowed as the load of tumor decrease. The circulating levels of VEGF seem not predict the response to bevacizumab in colorectal cancer patients at stage IV.
